论文部分内容阅读
成人T-细胞白血病/淋巴瘤(ATL)的急性型和淋巴瘤型经化疗后部分患者能获长生存,但一般预后很差。作者研究了1975年1月～1989年12月间114例攻击性ATL(包括急性型和淋巴瘤型),并追踪观察至1992年。多变量分析结果表明,一般状况不佳及高肌酸血症等二因素与攻击性ATL生存期有明显关系。同时指出腹水的有无亦是影响预后的重要因素,腹水的出现提示较好的预后。被研究的全部患者均给予联合化疗和同时加用或不加用放疗。其中20例患者(18.5%)获完全缓解(CR),53例(49.1%)获部分缓解(PR),35例对治疗无反应(NR)。CR患者平均生存期(MST)是25.1月,PR和NR 患者MST分别是7.3月和2.5月。CR或PR患者中15例的生存期在2年以上,而其他患者生存期则短于2年。将短生
Some patients with acute lymphoblastic T-cell leukemia / lymphoma (ATL) and lymphoma type have long survival after chemotherapy, but the general prognosis is poor. The authors studied 114 aggressive ATLs (including acute and lymphoid types) from January 1975 to December 1989 and followed up until 1992. Multivariate analysis showed that the two factors, such as poor general condition and hypermytosis, were significantly associated with aggressive ATL survival. Also pointed out whether the presence of ascites is also an important factor affecting the prognosis, the emergence of ascites better prognosis. All patients studied were given combination chemotherapy with and without radiotherapy. Twenty patients (18.5%) had complete remission (CR), 53 (49.1%) had partial response (PR) and 35 had no response to treatment (NR). The mean survival time (MST) for patients with CR was 25.1 months, and the MST for PR and NR patients were 7.3 months and 2.5 months respectively. Fifteen of the patients with CR or PR had a survival of over two years, while others had a survival of less than two years. Will be short-lived